Immunotherapy plus chemoradiation for esophageal small cell carcinoma
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation for esophageal small cell carcinoma. The goal is to see if this combination improves outcomes for patients who have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of small cell carcinoma of the esophagus.
- You either have early-stage cancer but cannot or choose not to have surgery, or you have more advanced cancer (T2-4N0-3M0).
- You are between 18 and 75 years old and are in generally good health (able to care for yourself).
- You have not had any prior treatment for this cancer.
- Your blood counts, liver, and kidney function meet specific minimum levels.
- You do not have an active autoimmune disease or severe heart condition, and you have not had certain prior treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs — one immunotherapy (serplulimab) plus two chemotherapies (etoposide and cisplatin) — given before surgery to shrink esophageal cancer and improve outcomes. It is for patients with limited-stage small cell carcinoma of the esophagus that has not spread far.
This study tests whether a new immunotherapy drug (adebrelimab) given with chemotherapy before standard chemoradiation can help people with advanced esophageal cancer that can't be removed with surgery. The goal is to see if this combination is safe and effective in shrinking tumors and controlling the disease.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a new approach for patients with a specific type of esophageal cancer that can be surgically removed. You would first receive a combination of an immunotherapy drug (adebrelimab) with chemotherapy and radiation, and then instead of immediate surgery, your doctor would monitor you closely to see if surgery is still needed. This may help some patients avoid surgery while keeping the cancer under control.
This trial tests adding an immunotherapy drug called adebrelimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination shrinks tumors more and improves outcomes.
Hear when a new Esophageal Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.